clinical settings, but calculated estimates of GFR appear to provide equally good information at much lower cost. In keeping with current best practice guidelines (12 ), we recommend that calculated estimates of GFR should supplement serum creatinine measurement alone and replace measured creatinine clearance.
cation) are independently associated with an increase in circulating fetal DNA (6 ) . Most studies, however, have had to rely on Y-chromosome loci, which can be used as fetus-specific markers for male fetuses. For this reason, the identification in maternal plasma of fetal-genderindependent markers, such as mRNA transcripts from genes expressed in fetal placenta, represented an important development in the field (4 ) . The concentrations of mRNA for corticotropin-releasing hormone (CRH) in maternal plasma are significantly higher in PE than in controls (5 ) , but no demonstration of relationships with gestational age and/or severity of PE have been reported.
The aim of this study was to evaluate and quantify the relationships of the concentration of circulating CRH mRNA in maternal plasma with both gestational age and the severity of PE.
We conducted a retrospective study in which the control group was 17 women with uncomplicated pregnancies (35% males) during the third trimester (median, 259 days since last menstrual period; minimum-maximum, 189 -281 days). Controls were matched with 17 pregnancies (53% males) affected by PE at the time of blood collection (median, 256 days since last menstrual period; minimum-maximum, 181-279 days). PE was defined as gestational hypertension (systolic pressure Ͼ140 mmHg or diastolic blood pressure Ͼ90 mmHg on at least two occasions after 20 weeks of gestation) with proteinuria (Ͼ0.3 g/day). Severe PE was defined as severe gestational hypertension (systolic pressure Ͼ160 mmHg or diastolic pressure Ն110 mmHg on at least two occasions after 20 weeks of gestation) with severe proteinuria (Ͼ5 g/day). Seven cases had mild PE, and six cases had severe PE. The PE status of one case was not documented. All women presented either at the University of Bologna (Bologna, Italy) or The Chinese University of Hong Kong, Prince of Wales Hospital (Hong Kong, China). All study participants provided written informed consent for the use of their biological specimens for research purposes. The ethics committees of both participating centers approved this protocol.
We mixed 1.6 mL of plasma with 2 mL of Trizol (Invitrogen) and 0.4 mL of chloroform (7 ). The mixture was centrifuged at 12 000g for 15 min at 4°C, and the aqueous layer was transferred to new tubes. One volume of 700 mL/L ethanol was added to one volume of the aqueous layer. The mixture was then applied to an RNeasy minicolumn (Qiagen) and processed according to the manufacturer's recommendations. Potential contaminating DNA was digested by use of a RNase-free DNase preparation (Qiagen) as described by the manufacturer. Total RNA was eluted in 30 L of RNase-free water and stored at Ϫ80°C.
One-step real-time quantitative reverse transcription-PCR was performed with the EZ rTth RNA PCR reagent set (Applied Biosystems) as described previously (5 ) . In brief, 5 L of extracted plasma was added to 20 L of reaction mixture, and real-time reverse transcription quantitative PCR for the CRH gene was performed in a PE Applied Biosystems 7700 Sequence detector. Each sample was analyzed in duplicate, and the corresponding calibration curve was run in parallel. Several negative water controls were also included in the analysis. The thermal profile used for the CRH gene was as follows: the reaction was initiated at 50°C for 2 min, followed by 60°C for 30 min. After denaturation at 95°C for 5 min, 40 cycles of PCR were carried out at 94°C for 20 s and 58°C for 1 min.
The absolute concentrations of CRH mRNA were expressed as copies/mL of plasma based on the following calculation:
where c is the concentration of CRH mRNA in plasma (copies/mL); Q is the quantity (copies/L) of CRH mRNA detected by the sequence detector; V RNA is the total volume of RNA obtained after extraction, i.e., 30 L; and V ext is the volume of plasma extracted, i.e., 1.6 mL. Sample analysis was performed without knowledge of the gestational age and disease status (affected or not affected). Median CRH mRNA concentrations as a function of increasing gestational age (expressed in days) were calculated by weighted log-linear regression. In addition, PE (PE absent/present) was added to the regression as a "dummy" variable. Thus, this variable could assume a value of either 0 (absent) or 1 (present). All mRNA values in both cases and controls were expressed as multiples of the median (MoM). The MoM values were illustrated in a box-and-whisker plot, and the comparisons across generated groups was performed with nonparametric statistics.
The unadjusted median mRNA concentrations for CRH in controls and in the PE cases were 100 (0 -568) copies/mL and 962 (284 -5896) copies/mL, respectively. The CRH mRNA concentration directly correlated with gestational age (P ϭ 0.045; t ϭ 2.096) and to PE (P Ͻ0.001; t ϭ 6.482; Table 1 and Fig. 1A ). The mean (SD) MoM values were 1.00 (1.48) and 9.35 (11.18) for controls and PE cases, respectively (P Ͻ0.001). For cases affected by mild PE, the mean MoM was 8.30 (3.68); for cases affected by severe PE the mean MoM was 10.38 (14.24) . The difference was not significant (Fig. 1B) . The median (minimum-maximum) gestational ages were 256 (209 -274) and 256 (181-279) days for those pregnancies affected by mild and severe PE, respectively. Because of the small sample size, no definitive conclusions can be reached about the estimated MoM values in mild and severe PE, but it is worth mentioning that the net difference for severe PE when compared with mild PE was ϩ 2 MoM.
A correlation between placental hormones and their respective maternal plasma mRNAs has been described previously (4 ) . Such a result is important because the abnormal hormonal profiles detected in numerous patho- logic conditions would allow a preliminary evaluation of plasma mRNA products having a potential discriminant ability (especially for monitoring and screening) for a specific disease. Placental CRH plays a major role controlling those mechanisms for the maintenance of pregnancy. Plasma CRH is significantly higher in women with preterm deliveries and significantly lower in women who delivered post term, when compared with those who delivered at term (8 ) . Such a mechanism, which begins at the first trimester, is a placental clock that triggers the onset of labor. CRH participates in the control of vascular tone in the human placenta, and it has been found in higher than expected concentrations in those conditions associated with vascular damage as well as PE (9 ), a disease that affects ϳ3-5% of pregnancies (10 ) . The pathogenesis of PE, although poorly understood, has been associated with apoptotic change of the villous trophoblasts (11 ) , possibly secondary to inadequate oxygenation of blood within the intervillous spaces (10 ) . The increases in circulating fetal DNA and RNA observed in PE (2 ) are likely to be epiphenomena of the apoptosis of such placental tissues, although 5-fold (6 ) and 10-fold (5 ) increases, respectively, were shown for fetal DNA and CRH mRNA even after adjustment for possible confounding factors (6 ) . Such increases in CRH mRNA concentrations, if also demonstrated for women who will eventually develop PE but are asymptomatic at the time of blood collection, would make CRH mRNA a promising tool for possible use in a screening program. It must be emphasized that in women who will eventually develop PE, a 2.5-fold increase in circulating fetal DNA has been observed (12 ) . Furthermore, for those women who screen positive for anomalies of the uterine arteries based on Doppler waveform (a current method for PE and fetal growth restriction screening), circulating fetal nucleic acid quantification could be used as an adjunct for better differentiation of those women who will develop the complications (13 ) . CRH mRNA, as described here, is an attractive candidate because of its gender-and polymorphism-independent nature. 
